Activated PI3K-delta syndrome in an Egyptian pediatric cohort with primary immune deficiency

Main Article Content

Alshymaa A. Ahmed
Alia A. El Shahaway
Sameh A. Hussien

Keywords

Primary immune deficiency, B lymphocytes, T lymphocytes, Activated PI3K Delta syndrome, Respiratory tract infections

Abstract

Background: Activated Phospho-Inositide 3 (PI3) Kinases Delta syndrome (APDS) can underlie primary immune deficiency. The prevalence and phenotypic characterization of these patients are not well described in Egypt.


Objectives: To describe patients with APDS in hospitalized children with recurrent respiratory tract infections with suspected primary immune deficiency.


Methods: 79 patients were included in the study. E1021K and E525K mutations of PI3K chain gene were screened by Sanger sequencing technique.


Results: one patient was heterozygous to E1021K mutation; a female child was diagnosed clinically as Combined Immune Deficiency with CD4 and B lymphopenia and markedly deficient IgG and increased IgM. The E525K mutation was not detected in our cohort.


Conclusions: Screening for APDS in patients with recurrent respiratory tract infections with undefined antibody deficiency or combined immune deficiency with or without bronchiectasis is required. These patients need great attention to benefit from the available treatment. Further studies on the Egyptian population are recommended to increase the knowledge about the prevalence and phenotypic characterization of this disease in Egypt.

Abstract 105 | PDF Downloads 106

References

1. Reda SM, Afifi HM, Amine MM. Primary immunodeficiency diseases in Egyptian children: a single-center study. J Clin Immunol. 2009;29(3):343-51.

2. Bousfiha A, Jeddane L, Picard C, et al. The 2017 IUIS Phenotypic Classification for Primary Immunodeficiencies. J Clin Immunol. 2018;38(1):129-43.

3. Routes J, Abinun M, Al-Herz W, et al. ICON: the early diagnosis of congenital immunodeficiencies. J Clin Immunol. 2014;34(4):398-424.

4. Wang X, Ding J, Meng L-h-h. PI3K isoform-selective inhibitors: next-generation targeted cancer therapies. Acta Pharmacol Sin. 2015;36(10):1170-6.

5. Tzenaki N, Papakonstanti EA. p110delta PI3 kinase pathway: emerging roles in cancer. Front Oncol. 2013;3:40.

6. Lucas CL, Kuehn HS, Zhao F, et al. Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110delta result in T cell senescence and human immunodeficiency. Nat Immunol. 2014;15(1):88-97.

7. Koyasu S. The role of PI3K in immune cells. Nat Immunol. 2003;4(4):313.

8. Angulo I, Vadas O, Garcon F, et al. Phosphoinositide 3-kinase delta gene mutation predisposes to respiratory infection and airway damage. Science. 2013;342(6160):866-71.

9. Michalovich D, Nejentsev S. Activated PI3 Kinase Delta Syndrome: From Genetics to Therapy. Ontiers Immunol. 2018;9(369).

10. Dornan GL, Siempelkamp BD, Jenkins ML, Vadas O, Lucas CL, Burke JE. Conformational disruption of PI3K regulation by immunodeficiency mutations in PIK3CD and PIK3R1. Proc Natl Acad Sci U S A. 2017;114(8):1982-7.

11. Arkwright PD, Gennery AR. Ten warning signs of primary immunodeficiency: a new paradigm is needed for the 21st century. Ann N Y Acad Sci. 2011;1238:7-14.

12. Peacock J, Peacock P. Oxford handbook of medical statistics. Research design, choosing a sample size. Oxford university press; 2011. p. 56-70.

13. Elgizouli M, Lowe DM, Speckmann C, et al. Activating PI3Kdelta mutations in a cohort of 669 patients with primary immunodeficiency. Clin Exp Immunol. 2016;183(2):221-9.

14. Hussien S, Abd El Salam M, Zidan M. Assessment of primary immunodeficiency disorders among children at Zagazig University Hospital. Zagazig Univ Med J. 2014;20(2):1-11.

15. Crank MC, Grossman JK, Moir S, et al. Mutations in PIK3CD can cause hyper IgM syndrome (HIGM) associated with increased cancer susceptibility. J Clin Immunol. 2014;34(3):272-6.

16. Coulter Ti, Chandra A, Bacon Cm, et al. Clinical spectrum and features of activated phosphoinositide 3-kinase delta syndrome: A large patient cohort study. J Allergy Clin Immunol. 2017;139(2), 597-606 e594.

17. Kracker S, Curtis J, Ibrahim MA, et al. Occurrence of B-cell lymphomas in patients with activated phosphoinositide 3-kinase syndrome. J Allergy Clin Immunol. 2014;134(1), 233-236. e233.

18. Suárez-Fueyo A, Barber DF, Martínez-Ara J, Zea-Mendoza AC, Carrera AC. Enhanced Phosphoinositide 3-Kinase activity is a frequent event in systemic lupus erythematosus that confers resistance to activation-induced T cell death. J Immunol. 2011;187(5):2376-85.

19. Fruman DA, Rommel C. PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discovery. 2014;13(2):140.

20. Bartok B, Boyle DL, Liu Y, et al. PI3 kinase is a key regulator of synoviocyte function in rheumatoid arthritis. Am J Pathol. 2012;180(5):1906-16.

21. Sriskantharajah S, Hamblin N, Worsley S, Calver AR, Hessel EM, Amour A. Targeting phosphoinositide 3-kinase for the treatment of respiratory diseases. Ann N Y Acad Sci. 2013;1280(1):35-9.

22. Cahn A, Hamblin J, Begg M, et al. Safety, pharmacokinetics and dose-response characteristics of GSK2269557, an inhaled PI3K inhibitor under development for the treatment of COPD. Pulm Pharmacol Ther. 2017;46:69-77.